Comparative Pharmacology
Head-to-head clinical analysis: DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR versus EMERPHED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR versus EMERPHED.
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR vs EMERPHED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Pseudoephedrine sulfate is an alpha-adrenergic receptor agonist causing vasoconstriction.
EMERPHED is a combination of ephedrine and phenylephrine. Ephedrine is a sympathomimetic amine that acts directly on alpha and beta adrenergic receptors and indirectly by releasing norepinephrine from nerve endings, causing vasoconstriction, bronchodilation, and increased heart rate and blood pressure. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.
One tablet (desloratadine 5 mg/pseudoephedrine sulfate 240 mg) orally once daily.
Adults: 1-2 capsules (25-50 mg ephedrine sulfate) orally every 3-4 hours as needed, not to exceed 150 mg in 24 hours.
None Documented
None Documented
Desloratadine: 27 hours (terminal); pseudoephedrine sulfate: 5-8 hours (terminal, dependent on urine pH).
Terminal elimination half-life: 3-6 hours (prolonged in renal impairment: up to 15 hours).
Desloratadine: 41% urine (metabolites), 47% feces (metabolites); pseudoephedrine sulfate: 70-90% renal (unchanged), 1% biliary.
Renal excretion of unchanged drug (~30-50%) and metabolites; minor biliary/fecal elimination (<10%).
Category A/B
Category C
Sympathomimetic
Sympathomimetic